|
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706 Issues : 12 per year Publisher : Excellent Publishers Email : editorijcmas@gmail.com / submit@ijcmas.com Editor-in-chief: Dr.M.Prakash Index Copernicus ICV 2018: 95.39 NAAS RATING 2020: 5.38 |
Pseudomonas aeruginosa is a clinically troublesome gram negative pathogen that causes a wide range of opportunistic infections and nosocomial outbreaks. Metallo beta lactamase have recently emerged one of the most worrisome resistance mechanisms to hydrolyse all beta lactam agents including carbapenems. Drug resistance in turn leads to prolonged hospital stay and increased expenditure, which causes increased cross infections and poorer clinical outcomes. The present study investigated the prevalence of resistance mechanisms among Multi Drug Resistant Pseudomonas aeruginosa (MDRPA) clinical isolates fromclinical laboratories. One hundred and twenty MDR P.aeruginosa isolates were obtained from 400clinical samples from clinical laboratories. Antimicrobial susceptibility testing was performed by disk diffusion method and all these isolates were found to be MDR. All the isolates were subjected to different phenotypic assays to detect the production of enzymes such as ESBL, AmpC and MBL. Further, quantitative evaluation of biofilm production was carried out by microtiter plate assay, since many studies have shown positive correlation between MDR and biofilm formation. Of the 120 MDR P. aeruginosa, 45.83% were resistant to imipenem and 54.16% to meropenem. All the isolates were sensitive to polymyxin B. MBL production (58.33%) was found to be the predominant resistance mechanism followed by ESBL production (45.83%). None of them showed AmpC production. 93.33% of the strains produced abundant biofilms. P. aeruginosa was shown to be predominant nosocomial pathogen showing resistance to most of the available antibiotics including carbapenems. MBL is shown to be predominant mechanism for development of resistance in the present study.